clinical trial · NCT03713658
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Janssen Research & Development, LLC·phase4·completed·n = 34
SchizophreniaRisperidone 3 mgPaliperidone Palmitate 50 mg eq.Paliperidone Palmitate 75 mg eq.Paliperidone Palmitate 100 mg eq.Paliperidone Palmitate 150 mg eq.Paliperidone Palmitate 175 mg eq.Paliperidone Palmitate 263 mg eq.Paliperidone Palmitate 350 mg eq.
brief summary
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.
started
Oct 18, 2018
primary completion
Dec 2, 2019
completion
Dec 2, 2019
last updated
Apr 27, 2025
official title
A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol